Open AccessThis article is
- freely available
Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines
Vaxin Inc, 19 Firstfield Road, Suite 200, Gaithersburg, Maryland 20878, USA
Received: 30 September 2012; in revised form: 22 October 2012 / Accepted: 25 October 2012 / Published: 1 November 2012
Abstract: The emergence of a highly pathogenic avian influenza virus H5N1 has increased the potential for a new pandemic to occur. This event highlights the necessity for developing a new generation of influenza vaccines to counteract influenza disease. These vaccines must be manufactured for mass immunization of humans in a timely manner. Poultry should be included in this policy, since persistent infected flocks are the major source of avian influenza for human infections. Recombinant adenoviral vectored H5N1 vaccines are an attractive alternative to the currently licensed influenza vaccines. This class of vaccines induces a broadly protective immunity against antigenically distinct H5N1, can be manufactured rapidly, and may allow mass immunization of human and poultry. Recombinant adenoviral vectors derived from both human and non-human adenoviruses are currently being investigated and appear promising both in nonclinical and clinical studies. This review will highlight the current status of various adenoviral vectored H5N1 vaccines and will outline novel approaches for the future.
Keywords: recombinant adenoviral vector; influenza vaccine; cross-protection; pandemic influenza; H5N1
Citations to this Article
Cite This Article
MDPI and ACS Style
Zhang, J. Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines. Viruses 2012, 4, 2711-2735.
Zhang J. Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines. Viruses. 2012; 4(11):2711-2735.
Zhang, Jianfeng. 2012. "Advances and Future Challenges in Recombinant Adenoviral Vectored H5N1 Influenza Vaccines." Viruses 4, no. 11: 2711-2735.